We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
American Bio Medica Corporation (CE) | USOTC:ABMC | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.002 | 0.00 | 01:00:00 |
|
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
FORM
12b-25
|
SEC FILE NUMBER
|
|
|
0-28666
|
||
|
|
|
|
|
|
|
CUSIP NUMBER
|
|
NOTIFICATION
OF LATE FILING
|
024600
|
(Check one):
|
☑
|
Form
10-K
|
☐
|
Form
20-F
|
☐
|
Form
11-K
|
☐
|
Form
10-Q
|
☐
|
Form
10-D
|
☐
|
Form
N-SAR
|
☐
|
Form
N-CSR
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For Period Ended:
December
31, 2019
|
|||||||||||
|
|
|
|
|||||||||||
|
|
|
|
|
||||||||||
|
☐
|
Transition
Report on Form 10-K
|
||||||||||||
|
|
|
|
|
||||||||||
|
☐
|
Transition
Report on Form 20-F
|
||||||||||||
|
|
|
|
|
||||||||||
|
☐
|
Transition
Report on Form 11-K
|
||||||||||||
|
|
|
|
|
||||||||||
|
☐
|
Transition
Report on Form 10-Q
|
||||||||||||
|
|
|
|
|
||||||||||
|
☐
|
Transition
Report on Form N-SAR
|
||||||||||||
|
|
|
|
|
||||||||||
|
|
|
For the Transition
Period Ended:
|
|
(a)
|
The reason
described in reasonable detail in Part III of this form could not
be eliminated without unreasonable effort or expense
|
|
|
|
☒
|
(b)
|
The subject annual
report, semi-annual report, transition report on Form 10-K, Form
20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will
be filed on or before the fifteenth calendar day following the
prescribed due date; or the subject quarterly report or transition
report on Form 10-Q or subject distribution report on Form 10-D, or
portion thereof, will be filed on or before the fifth calendar day
following the prescribed due date; and
|
|
|
|
|
(c)
|
The
accountant’s statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
|
|
|
|
(1)
|
Name and telephone
number of person to contact in regard to this
notification
|
||||||||
|
|||||||||
|
Melissa
A. Waterhouse
|
|
(518)
|
|
758-8158
|
||||
|
(Name)
|
|
(Area
Code)
|
|
(Telephone
Number)
|
||||
|
|||||||||
(2)
|
Have all other
periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such
shorter period that the registrant was required to file such
report(s) been filed? If answer is no, identify
report(s).
|
||||||||
Yes
|
☒
|
No
|
☐
|
|
|||||
|
|
||||||||
|
|||||||||
(3)
|
Is it anticipated
that any significant change in results of operations from the
corresponding period for the last fiscal year will be reflected by
the earnings statements to be included in the subject report or
portion thereof?
|
||||||||
Yes
|
☐
|
No
|
☒
|
|
|||||
|
|||||||||
|
If so, attach an
explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.
|
|
||||
Date: March 30, 2020
|
|
|
By:
|
/s/ Melissa A.
Waterhouse
|
|
|
|
|
Melissa A.
Waterhouse
|
|
|
|
|
Chief Executive
Officer / Pricipal Financial Officer
|
1 Year American Bio Medica (CE) Chart |
1 Month American Bio Medica (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions